Puxitatug samrotecan, a novel B7-H4-targeting antibody-drug conjugate, demonstrated objective response rates of 34.6-38.5% in patients with advanced or metastatic endometrial cancer in the phase 1/2a BLUESTAR study.
The Phase III KEYNOTE-522 trial demonstrates a statistically significant overall survival advantage with neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer.
AZD8205, a novel antibody-drug conjugate, demonstrates a manageable safety profile in heavily pretreated patients with advanced or metastatic solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.